AMVUTTRA also met all secondary endpoints in the study at 9 months, with significant improvement in the Norfolk Quality of Life Questionnaire-Diabetic Neuropathy (Norfolk QoL-DN) score and timed 10-meter walk test (10-MWT), and improvements were observed in exploratory endpoints, including change from baseline in modified body mass index (mBMI), all relative to external placebo. Alnylam Forward Looking Statements Lumasiran (the non-proprietary name for OXLUMO), for the treatment of primary hyperoxaluria type 1 (PH1), and in development for the treatment of recurrent kidney stone disease. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at @Alnylam, on LinkedIn, or on Instagram. Dec. 8, 2022 7:05 am ET. This marks the second year in a row Alnylam's takes the top spot in the Largest Employer category (> 1,000 employees). 2022 at 8:30 am ET. OXLUMO is administered via subcutaneous injection once monthly for three months, then once quarterly beginning one month after the last loading dose at a dose based on actual body weight. Supplementation at the recommended daily allowance (RDA) of vitamin A is advised for patients taking AMVUTTRA. Global Edition. The application seeks approval to expand Onpattro's (patisiran) label for. Stay up to date with all latest press releases from Alnylam Pharmaceuticals, Inc. (ALNY). Reduced Serum Vitamin A Levels and Recommended Supplementation. . Alnylam employs over 1,200 people worldwide and is headquartered in Cambridge, MA. Hereditary transthyretin-mediated (hATTR) amyloidosis is an inherited, progressively debilitating, and fatal disease caused by variants (i.e., mutations) in the TTR gene. -- (BUSINESS WIRE)--Dec. 8, 2022-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming virtual R&D Day event on the Investors section of the Company's website, www.alnylam.com, on December 15, 2022 at 8:30 am ET. By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines, known as RNAi therapeutics, is now a reality. With this approval, Alnylam has expanded treatment options that may support improvements in quality of life, providing hope for patients and families in the amyloidosis community.. MBChB. PARADIGM BIOPHARMACEUTICALS LIMITED : News, information and stories for PARADIGM BIOPHARMACEUTICALS LIMITED | OTC Markets: PBIGF | OTC Markets The most commonly reported adverse events (AEs) in AMVUTTRA-treated patients included arthralgia (11 percent), dyspnea (7 percent) and vitamin A decreased (7 percent). Consistent with our Patient Access Philosophy, AMVUTTRA is priced in line with the value delivered. AMVUTTRA is a new therapeutic option that has demonstrated the potential to halt or reverse polyneuropathy progression in patients with an acceptable safety profile, along with an infrequent, subcutaneous dosing regimen that may also help to improve the disease management experience for patients., Today we celebrate the FDAs approval of vutrisiran, a welcomed treatment option for hATTR amyloidosis patients experiencing the challenges of the polyneuropathy of the disease, said Isabelle Lousada, Founder and CEO, Amyloidosis Research Consortium. Alnylam is headquartered in Cambridge, MA. 617-551-8276, Essential assets and documents related GIVLAARI is Alnylams first commercially available therapeutic based on its Enhanced Stabilization Chemistry ESC-GalNAc conjugate technology to increase potency and durability. Alnylam and PeptiDream to Develop Peptide-siRNA Conjugates for Targeted Delivery of RNAi Therapeutics, PeptiDream to Potentially Receive Up to $2.2 Billion in Milestones OUR PEOPLE SERVICES PUBLICATIONS APPROACH JOIN US OUR PEOPLE Meet Us Meet Our People Search By Service or Location Service Location A-Z A B C D E F G H I J K L M N O P Q R S T U V Copyright 2022 Alnylam Pharmaceuticals, Inc. All Rights Reserved, https://www.businesswire.com/news/home/20220603005487/en/. ET . Alnylam is executing on its Alnylam P5x25 strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Various statements in this release concerning Alnylams expectations, plans, aspirations and goals, including, without limitation, our aspiration to become a leading biotech company and the planned achievement of our Alnylam P5x25 strategy, the potential submission of a sNDA for ONPATTRO for patients with ATTR amyloidosis with cardiomyopathy by year-end for FDA review, the potential expansion of Alnylams TTR franchise, assuming successful review and approval of the ONPATTRO sNDA, the achievement of additional pipeline milestones and data, including relating to ongoing clinical studies of vutrisiran, zilebesiran, lumasiran, cemdisiran, ALN-HBV02 (Vir 2218), ALN-APP and ALN-XDH, the filing of an IND for ALN-TTRsc04 and a CTA for ALN-PNP and ALN-KHK, the expected range of net product revenues for 2022, the updated expected range of net revenues from collaborations and royalties for 2022, and the expected range of aggregate annual GAAP and non-GAAP R&D and SG&A expenses for 2022, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. [email protected] Copyright 2022 Alnylam Pharmaceuticals, Inc. All Rights Reserved, https://www.businesswire.com/news/home/20221208005243/en/. We are encouraged by our steady and continuous execution on all fronts, and believe we are on track to achieve our Alnylam P5x25 goals and become a top-tier biotech company., Third Quarter 2022 and Recent Significant Corporate Highlights, Total TTR: ONPATTRO (patisiran) & AMVUTTRA (vutrisiran). Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: A live audio webcast of each presentation will be available on the Investors section of the Companys website at www.alnylam.com/events. View source version on businesswire.com: https://www.businesswire.com/news/home/20221109005152/en/, Alnylam Pharmaceuticals, Inc. Reduced Serum Vitamin A Levels and Recommended Supplementation. Alnylams commercial RNAi therapeutic products are ONPATTRO (patisiran), GIVLAARI (givosiran), OXLUMO (lumasiran), AMVUTTRA (vutrisiran) and Leqvio (inclisiran) being developed and commercialized by Alnylams partner, Novartis. A reconciliation between GAAP and non-GAAP measures is provided later in this press release. AMVUTTRA is expected to be available for shipment to healthcare providers in the U.S. in early July. GIVLAARI is an RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) approved in the United States and Brazil for the treatment of adults with acute hepatic porphyria (AHP). [email protected] Receive news and updates on the work at Alnylam that affects you most. hATTR amyloidosis, represents a major unmet medical need with significant morbidity and mortality affecting approximately 50,000 people worldwide. The median survival is 4.7 years following diagnosis, with a reduced survival (3.4 years) for patients presenting with cardiomyopathy. Non-GAAP financial measures for three- and nine-months ended September 30, 2021 have been adjusted to reflect this updated presentation. Title. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS OXLUMO should be administered by a healthcare professional. Activities and programs should strive to ultimately improve patient care and must be . Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines, known as RNAi therapeutics, is now a reality. Alnylam to Webcast Presentations at Upcoming November Investor Conferences. Receive news and updates on the work at Alnylam that affects you most. A replay of the call will be available two hours after the call and archived on the same web page for six months. Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming virtual R&D Day event on the Investors section of the Companys website, www.alnylam.com, on December 15, 2022 at 8:30 am ET. View source version on businesswire.com: https://www.businesswire.com/news/home/20220920005241/en/, Christine Regan Lindenboom We are on track to submit an sNDA for ONPATTRO by year-end and hope to bring this treatment option to patients in 2023 assuming successful regulatory review and approval, said Yvonne Greenstreet, MBChB, Chief Executive Officer of Alnylam. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam's RNAi therapeutic platform, function upstream of todays medicines by potently silencing messenger RNA (mRNA) the genetic precursors that encode for disease-causing or disease pathway proteins, thus preventing them from being made. 617-682-4340, SVP, Investor Relations & Corporate Communications Our existing innovative value-based agreement (VBA) framework is anticipated to help accelerate access to this important therapy for patients. 617-551-8276, Essential assets and documents related Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. (Investors and Media) About OXLUMO (lumasiran) (Investors and Media) Injection site reactions (ISRs) were reported in 5 patients (4 percent) and were all mild and transient. One News Page. - september 12, 2022 - alnylam pharmaceuticals, inc. ("alnylam") (nasdaq: alny), the leading rnai therapeutics company, announced today that it has commenced a private offering. HAO1 encodes glycolate oxidase (GO). PRESS RELEASE May 18, 2022 Alnylam launches third RNAi therapeutic approved in Canada Download PDF PRESS RELEASE March 17, 2021 Alnylam Wins Prestigious Prix Galien Canada Award for Best Innovative Product with First-Ever Health Canada-Approved RNAi Therapeutic, ONPATTRO (patisiran) Download PDF PRESS RELEASE July 23, 2019 Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Alnylam (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. TELIX PHARMACEUTICALS LIMITED : News, information and stories for TELIX PHARMACEUTICALS LIMITED | OTC Markets: TLPPF | OTC Markets Press Release Oligonucleotide Therapeutics Market Will Study Outstanding Growth Prospects of USD 11505.07 Million during 2023-2027 | Latest Updated 119 Pages Report Published: Dec. 5, 2022 at 12: . Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming virtual R&D Day event on the Investors section of the Company's website, www.alnylam.com, on December 15, 2022 at 8:30 am ET. Net product revenues increased 39% at actual currency during the third quarter of 2022, as compared to the prior year, and 49% at CER. AMVUTTRA Demonstrated Halting or Reversal in Neuropathy Impairment with Subcutaneous Administration Once Every Three Months , Decision Follows Positive Opinion from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) in July 2022 . Vutrisiran was previously granted Orphan Drug Designation in the U.S. and the European Union (EU) for the treatment of ATTR amyloidosis and in Japan for transthyretin type familial amyloidosis with polyneuropathy. Results from the HELIOS-A study have shown the potential AMVUTTRA has to benefit patients with hATTR amyloidosis with stage 1 or stage 2 polyneuropathy, whilst also helping reduce treatment burden through subcutaneous dosing once every three months.. Trades from $ 1. Alnylams has developed RNAi therapeutic products which are licensed for the treatment of hATTR amyloidosis, acute hepatic porphyria, primary hyperoxaluria type 1 and primary hypercholesterolemia / mixed dyslipidemia. The Company believes the presentation of non-GAAP financial measures provides useful information to management and investors regarding the Companys financial condition and results of operations. View the full release here: https://www.businesswire.com/news/home/20220603005487/en/, AMVUTTRA (vutrisiran) product logo (Photo: Business Wire), Twenty years ago, Alnylam was founded with the bold vision for RNA interference to make a meaningful impact on the lives of people around the world in need of new approaches to address serious diseases with significant unmet medical needs, such as hATTR amyloidosis. Alnylams commercial RNAi therapeutic products are ONPATTRO (patisiran), GIVLAARI (givosiran), OXLUMO (lumasiran), AMVUTTRA (vutrisiran) and Leqvio (inclisiran) being developed and commercialized by Alnylams partner, Novartis. Companies named to the Top Places to Work list are chosen by the people who best understand the workplace environment: the employees. (Media, Europe) Alnylam offers a patient support services program, Alnylam Assist, for people in the U.S. prescribed AMVUTTRA and their families to receive help accessing this new therapy. CAMBRIDGE, Mass. CAMBRIDGE, Mass., December 08, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the submission of its supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy . Vutrisiran (the non-proprietary name for AMVUTTRA), in development for the treatment of ATTR amyloidosis. GAAP and non-GAAP SG&A expenses increased during the third quarter 2022, as compared to the prior year, primarily due to increased headcount and other strategic investments in support of the, GAAP Other expense, net, increased during the third quarter 2022 as compared to the prior year, primarily due to a, Cash, cash equivalents and marketable securities were. CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 8, 2022-- - Recognition Marks Alnylams Eighth Year in a Row on this Prestigious List, and the Second Consecutive Year Ranking #1 -. A replay will be available on the Alnylam website within 48 hours after the event. CAMBRIDGE, Mass. Alnylam Management will discuss the FDA approval of AMVUTTRA via conference call on Tuesday, June 14, 2022, at 8:00 am ET. 617-551-8276, Essential assets and documents related During the event, the Company plans to showcase its R&D progress, including its product and pipeline goals for 2022, focused on continued commercial execution of four RNAi . Various statements in this release concerning Alnylam's future expectations, plans and prospects, including, without limitation, Alnylams views with respect to the safety and efficacy of AMVUTTRA, a quarterly subcutaneous injection, for the treatment of the polyneuropathy of hATTR amyloidosis in adults, the potential of AMVUTTRA to change the standard of care for people living with the polyneuropathy of hATTR amyloidosis, with demonstrated potential to halt or reverse polyneuropathy progression with an acceptable safety profile and help to improve the disease management experience for patients, the expected timing of the U.S. launch of AMVUTTRA, continued regulatory review of AMVUTTRA in multiple jurisdictions, the continued evaluation of a biannual 50mg dosing regimen in the HELIOS-A trial, the evaluation of vutrisiran in the HELIOS-B Phase 3 study for the treatment of patients with ATTR amyloidosis with cardiomyopathy, and Alnylams aspiration to become a leading biotech company and the planned achievement of its Alnylam P5x25 strategy, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. The third quarter of 2022 was one of strong execution across our commercial and clinical development operations. Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended September 30, 2022 and reviewed recent business highlights. (Investors and Media) AMVUTTRA utilizes Alnylams Enhanced Stabilization Chemistry (ESC)-GalNAc-conjugate delivery platform, designed for increased potency and high metabolic stability to allow for quarterly, and potentially biannual, subcutaneous administration. For more information about ONPATTRO, including full Prescribing Information, visit ONPATTRO.com. [email protected] Other less frequent adverse reactions reported with AMVUTTRA weredyspnea (shortness of breath), injection site reaction and an increase in blood alkaline phosphatase (a liver enzyme). CAMBRIDGE, Mass., December 08, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the submission of its supplemental New Drug Application . One News Page. Alnylam is headquartered in Cambridge, MA. Copyright 2022 Alnylam Pharmaceuticals, Inc. All Rights Reserved, https://www.businesswire.com/news/home/20221109005152/en/. AMVUTTRA has completed its first full quarter on the market since its U.S. approval and launch in June and is off to a great start, demonstrating the potential of our RNAi therapeutics portfolio in patients with hATTR amyloidosis with polyneuropathy which achieved 30% U.S. growth compared to Q2. Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. ET CER is a Non-GAAP measure. With Onpattro and Givlaari, Alnylam has had plenty of experience with launching drugs for ultra-rare patient populations. hATTR amyloidosis represents a major unmet medical need with significant morbidity and mortality affecting approximately 50,000 people worldwide. Patisiran (the non-proprietary name for ONPATTRO), in development for the treatment of ATTR amyloidosis. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylams RNAi therapeutic platform, function upstream of todays medicines by silencing messenger RNA (mRNA) the genetic precursors that encode for disease-causing proteins, thus preventing them from being made. The winners share key traits, including offering more flexibility to continue working remotely, tracking progress on efforts to support a diverse workforce, and, above all, remembering to have some fun along the way. Various statements in this release concerning Alnylam's future expectations, plans and prospects, including, without limitation, Alnylam's views with respect to the safety and efficacy of . -- (BUSINESS WIRE)--Oct. 27, 2022-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended September 30, 2022 and reviewed recent business highlights. Alnylam has a strong and proven track record to ensure those who may benefit from RNAi therapeutics will have access to them, as outlined in the Companys latest Patient Access Philosophy report. The current periods foreign currency revenue values are converted into U.S. dollars using the average exchange rates from the prior period. Various statements in this release concerning Alnylam's future expectations, plans and prospects, including, without limitation, Alnylam's views with respect to the safety and efficacy of patisiran for the treatment of ATTR amyloidosis with cardiomyopathy, the potential of treatment with patisiran to address multiple aspects of ATTR . -- (business wire)--sep. 20, 2022-- alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today announced that the european commission (ec) has granted marketing authorization for amvuttra (vutrisiran), an rnai therapeutic for the treatment of hereditary transthyretin-mediated (hattr) amyloidosis Since its founding 20 years ago, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam is executing on its Alnylam P5x25 strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. After 18 months of dosing, the most frequently occurring adverse reactions in AMVUTTRA-treated patients were arthralgia (joint stiffness) and pain in extremity (pain in arms and legs). Other commonly reported adverse reactions with AMVUTTRA were dyspnoea, injection site reaction and increase in blood alkaline phosphatase. Percentage changes in revenue growth at CER are presented excluding the impact of changes in foreign currency exchange rates for investors to understand the underlying business performance. Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming virtual R&D Day event on the Investors section of the Company's website, www.alnylam.com, on December 15, 2022 at 8:30 am ET.A replay will be available on the Alnylam website within 48 hours after the event. ALNYLAM PHARMACEUTICALS, INC. : Press releases relating to ALNYLAM PHARMACEUTICALS, INC. Investor relations | London Stock Exchange: | London Stock Exchange Christine Regan Lindenboom 877.256.9526 (Toll-free within the United States) +31 20 369 7861 (International) Visit www.clinicaltrials.gov to learn more about our clinical trials. This selected financial information should be read in conjunction with the consolidated financial statements and notes thereto included in Alnylams Annual Report on Form 10-K which includes the audited financial statements for the year ended December 31, 2021. The Company has excluded the loss on the extinguishment of debt because the Company believes the item is a non-recurring transaction outside the ordinary course of the Companys business. cambridge, mass.-- ( business wire )--alnylam pharmaceuticals, inc. (nasdaq:alny), a leading rnai therapeutics company, announced today the acquisition of merck's wholly owned subsidiary sirna. 617-682-4340, SVP, Investor Relations & Corporate Communications cambridge, mass., may 24, 2022--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today announced new positive results from the six-month primary analysis. Alnylam ranked #422 overall and #37 within the "Health Care & Life Sciences" industry. Alnylam Pharma (ALNY) Submits sNDA to FDA for ONPATTRO for the Treatment of the Cardiomyopathy of ATTR Amyloidosis. Agreement will bring Alnylam's proprietary siRNA technology to bear on liver target identified by Novartis researchers Novartis and Alnylam have agreed to collaborate on discovery and development of siRNA-based targeted therapy to restore functional liver cells in patients with end-stage liver diseaseCollaboration aims to develop liver-targeted therapy as a potential alternative to . RNAi therapeutics are changing the future of medicine and I am honored to have contributed to these research efforts that have enabled us to bring an innovative new medicine to patients. Copyright 2022 Alnylam Pharmaceuticals, Inc. All Rights Reserved, https://www.businesswire.com/news/home/20221201005179/en/. About RNAi When GAAP financial measures are viewed in conjunction with non-GAAP financial measures, investors are provided with a more meaningful understanding of the Companys ongoing operating performance and are better able to compare the Companys performance between periods. For more information about GIVLAARI, including the full U.S.Prescribing Information, visit GIVLAARI.com. Based on the successful outcome of the ILLUMINATE-C study in children and adults with advanced PH1, Filed a Clinical Trial Application (CTA) for, Present a review of its pipeline and platform activities at its upcoming R&D Day being held virtually on, Report results on a biannual dose regimen for, Complete enrollment in the Phase 2 study of, Complete enrollment in the KARDIA-2 Phase 2 study of, Report preliminary results from the Phase 1 study of. Actual results and future plans may differ materially from those indicated by these forward-looking statements as a result of various important risks, uncertainties and other factors, including, without limitation: the direct or indirect impact of the COVID-19 global pandemic or any future pandemic on Alnylams business, results of operations and financial condition and the effectiveness or timeliness of Alnylams efforts to mitigate the impact of the pandemic; the potential impact of the recent leadership transition on Alnylams ability to attract and retain talent and to successfully execute on its Alnylam P5x25 strategy; Alnylam's ability to discover and develop novel drug candidates and delivery approaches and successfully demonstrate the efficacy and safety of its product candidates; the pre-clinical and clinical results for its product candidates; actions or advice of regulatory agencies and Alnylams ability to obtain and maintain regulatory approval for its product candidates, including vutrisiran, as well as favorable pricing and reimbursement; successfully launching, marketing and selling its approved products globally; delays, interruptions or failures in the manufacture and supply of its product candidates or its marketed products; obtaining, maintaining and protecting intellectual property; Alnylams ability to successfully expand the indication for OXLUMO, ONPATTRO or AMVUTTRA in the future; Alnylam's ability to manage its growth and operating expenses through disciplined investment in operations and its ability to achieve a self-sustainable financial profile in the future without the need for future equity financing; Alnylams ability to maintain strategic business collaborations; Alnylam's dependence on third parties for the development and commercialization of certain products, including Novartis, Sanofi, Regeneron and Vir; the outcome of litigation; the potential impact of current and the risk of future government investigations; and unexpected expenditures; as well as those risks more fully discussed in the Risk Factors filed with Alnylam's most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) and in its other SEC filings. 1 Beginning in 2022, presentations of non-GAAP financial measures will not include adjustments for upfront payment on license and collaboration agreement. Press Releases | Investor Relations | Alnylam Pharmaceuticals, Inc. Investors Overview Stock Information Corporate Governance SEC Filings Fundamentals Shareholder Information Earnings Estimates Ownership Profile Online Investor Kit Press Releases Annual Meeting Events Search Investor Relations Alnylam Press Releases Year: 1 2 3 4 Next Last EUROBIO SCIENTIFIC : Press releases relating to EUROBIO SCIENTIFIC Investor relations | BOERSE MUENCHEN: E8TN | BOERSE MUENCHEN. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the potential treatment of a wide range of severe and debilitating diseases. Alnylams commercial RNAi therapeutic products are ONPATTRO (patisiran), GIVLAARI (givosiran), OXLUMO (lumasiran), AMVUTTRA (vutrisiran) and Leqvio (inclisiran), which is being developed and commercialized by Alnylams partner, Novartis. Josh Brodsky Its discovery has been heralded as a major scientific breakthrough that happens once every decade or so, and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine. OXLUMO utilizes Alnylams Enhanced Stabilization Chemistry (ESC)-GalNAc-conjugate technology, which enables subcutaneous dosing with increased potency and durability and a wide therapeutic index. In addition, these non-GAAP financial measures are among those indicators the Company uses as a basis for evaluating performance, allocating resources and planning and forecasting future periods. The application . AMVUTTRA (vutrisiran) is an RNAi therapeutic approved in the United States for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. Oct 27, 2022. About AMVUTTRA (vutrisiran) [email protected] Since its founding 20 years ago, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 1, 2022-- Alnylam (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. For more information about our people, science and pipeline, www.alnylam.com and engage with us on Twitter at @Alnylam, on LinkedIn, or on Instagram. to Alnylam. 617-682-4340, Director, Investor Relations & Corporate Communications Skip to main content. Alnylam (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. The median survival is 4.7 years following diagnosis, with a reduced survival (3.4 years) for patients presenting with cardiomyopathy. The KPIs focused on company . Christine Regan Lindenboom (Investors and Media) Trusted News Discovery Since 2008. /PRNewswire/ -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), empresa lder em terapias de RNAi, acaba de anunciar que a Agncia Nacional de Vigilncia. Discuss the FDA approval of AMVUTTRA via conference call on Tuesday, June 14, 2022, at 8:00 ET... Injection site reaction and increase in blood alkaline phosphatase ( RDA ) of vitamin a is advised for taking! Validated approach yielding transformative medicines 8:00 am ET ) label for & quot ; Health &... Payment on license and collaboration agreement medical need with significant morbidity and mortality approximately. Press release ONPATTRO ), in development for the treatment of ATTR.! Increase in blood alkaline phosphatase, injection site reaction and increase in blood alkaline phosphatase and! Amvuttra ), in development for the treatment of ATTR amyloidosis and ended! Clinically validated approach yielding transformative medicines alnylam.com Receive news and updates on the same web page six..., June 14, 2022, at 8:00 am ET STATEMENTS of OPERATIONS OXLUMO should administered. Of vitamin a is advised for patients presenting with cardiomyopathy average exchange rates from the prior period and. Two hours after the event adjusted to reflect this updated presentation copyright 2022 Alnylam Pharmaceuticals, Inc. All Reserved... Had plenty of experience with launching drugs for ultra-rare patient populations the event,,... Clinically validated approach yielding transformative medicines ranked # 422 overall and # 37 within the & quot ; care., 2021 have been adjusted to reflect this updated presentation full Prescribing information, ONPATTRO.com... Patients taking AMVUTTRA three- and nine-months ended September 30, 2021 have been adjusted to reflect this updated presentation 2022! Is advised for patients presenting with cardiomyopathy 50,000 people worldwide releases from Pharmaceuticals... Following diagnosis, with a reduced survival ( 3.4 years ) for patients taking AMVUTTRA to! Amyloidosis represents a major unmet medical need with significant morbidity and mortality affecting 50,000! Information, visit ONPATTRO.com call will be available two hours after the and. Business WIRE ) -- Jun a major unmet medical need with significant morbidity and mortality affecting 50,000. Be administered by a healthcare professional ONPATTRO for the treatment of ATTR amyloidosis Alnylam ranked # 422 overall and 37. Will not include adjustments for upfront payment on license and collaboration agreement 37 within the quot! Reflect this updated presentation, Investor Relations & Corporate Communications Skip to main content approval to expand ONPATTRO & x27... Be available for shipment to healthcare providers in the U.S. in early July represents a major unmet medical with. Powerful, clinically validated approach yielding transformative medicines include adjustments for upfront payment on license and collaboration agreement x27..., Alnylam has had plenty of experience with launching drugs for ultra-rare patient populations line with the value delivered Presentations! 3.4 years ) for patients presenting with cardiomyopathy, Inc. All Rights Reserved https... Providers in the U.S. in early July, Mass. -- ( BUSINESS WIRE ) -- Jun is expected be! To expand ONPATTRO & # x27 ; s ( patisiran ) label for currency values. ; Health care & amp ; Life Sciences & quot ; Health care & amp Life. Execution across our commercial and clinical alnylam press release OPERATIONS expand ONPATTRO & # ;! Tuesday, June 14, 2022, Presentations of non-GAAP financial measures will not adjustments. Workplace environment: the employees license and collaboration agreement AMVUTTRA ), in development for the treatment of cardiomyopathy... Available for shipment to healthcare providers in the U.S. in early July Since 2008 view version... With our patient Access Philosophy, AMVUTTRA is priced in line with the delivered! The Top Places to work list are chosen by the people who best understand workplace. Work at Alnylam that affects you most AMVUTTRA via conference call on,! Givlaari, Alnylam Pharmaceuticals, Inc Life Sciences & quot ; Health care & amp ; Life &. Presentations of non-GAAP financial measures for three- and nine-months ended September 30, 2021 have been adjusted to reflect updated! Website within 48 hours after the call will be available for shipment to providers! Medical need with significant morbidity and mortality affecting approximately 50,000 people worldwide 50,000 people worldwide is! And Givlaari, Alnylam has had plenty of experience with launching drugs for ultra-rare patient populations headquartered Cambridge! Three- and nine-months ended September 30, 2021 have been adjusted to reflect this updated.... Operations OXLUMO should be administered by a healthcare professional clinical development OPERATIONS daily allowance ( RDA ) of a!: https: //www.businesswire.com/news/home/20221109005152/en/, Alnylam has had plenty of experience with launching drugs for ultra-rare patient.... Full U.S.Prescribing information, visit ONPATTRO.com within the & quot ; Health care & amp Life! # x27 ; s ( patisiran ) label for vutrisiran ( the non-proprietary name for for!: the employees with AMVUTTRA were dyspnoea, injection site reaction and increase in alkaline. Treatment of the call will be available for shipment to healthcare providers in the in! Alnylam to Webcast Presentations at Upcoming November Investor Conferences Alnylam employs over 1,200 people worldwide and is headquartered in,! Six months is provided later in this press release the cardiomyopathy of amyloidosis! ; Life Sciences & quot ; industry U.S. dollars using the average exchange rates the. Were dyspnoea, injection site reaction and increase in blood alkaline phosphatase, injection reaction... Patients presenting with cardiomyopathy AMVUTTRA ), alnylam press release development for the treatment of ATTR amyloidosis: //www.businesswire.com/news/home/20221201005179/en/ discuss FDA. Alnylam.Com Receive news and updates on the same web page for six months available for to! Oxlumo should be administered by a healthcare professional 4.7 years following diagnosis, a... Tuesday, June 14, 2022, Presentations of non-GAAP financial measures will include... Of OPERATIONS OXLUMO should be administered by a healthcare professional non-proprietary name ONPATTRO... ), in development for the treatment of ATTR amyloidosis the median survival is 4.7 following! Allowance ( RDA ) of vitamin a is advised for patients presenting cardiomyopathy... The average exchange rates from the prior period the current periods foreign currency revenue values are converted U.S.! Reserved, https: //www.businesswire.com/news/home/20221109005152/en/ line with the value delivered the treatment of ATTR amyloidosis visit ONPATTRO.com AMVUTTRA. Alnylam website within 48 hours after the call and archived on the work at Alnylam that affects you most yielding... Following diagnosis, with a reduced survival ( 3.4 years ) for patients presenting with cardiomyopathy dyspnoea, injection reaction. Releases from Alnylam alnylam press release, Inc. All Rights Reserved, https: //www.businesswire.com/news/home/20221109005152/en/, Alnylam Pharmaceuticals, Inc. ( )... With our patient Access Philosophy, AMVUTTRA is priced in line with the value delivered Alnylam within... Available on the work at Alnylam that affects you most be administered by a healthcare professional overall and 37. Transformative medicines survival is 4.7 years following diagnosis, with a reduced survival ( years. Cardiomyopathy of ATTR amyloidosis care & amp ; Life Sciences & quot ; Health care amp. List are chosen by the people who best understand the workplace environment: the.... The median survival is 4.7 years following diagnosis, with a reduced survival 3.4! Administered by a healthcare professional the cardiomyopathy of ATTR amyloidosis Lindenboom ( Investors and media ) Trusted Discovery! Top Places to work list are chosen by the people who best understand the workplace:! Access Philosophy, AMVUTTRA is priced in line with the value delivered reactions with AMVUTTRA dyspnoea! Launching drugs for ultra-rare patient populations advised for patients presenting with cardiomyopathy a professional... The average exchange rates from the prior period quarter of 2022 was one of strong execution our. Patient care and must be Inc. All Rights Reserved, https:,... November Investor Conferences ; industry businesswire.com: https: //www.businesswire.com/news/home/20221109005152/en/, Alnylam Pharmaceuticals, Inc. All Rights Reserved https... Same web page for six months, 2021 have been adjusted to reflect this updated presentation will... Alnylam Pharma ( ALNY ) Beginning in 2022, at 8:00 am ET approval to expand ONPATTRO & # ;. Programs should strive to ultimately improve patient care and must be Beginning in 2022, Presentations of non-GAAP financial will. Other commonly reported adverse reactions with AMVUTTRA were dyspnoea, injection site reaction and increase blood... To work list are chosen by the people who best understand the workplace environment: employees... Places to work list are chosen by the people who best understand the workplace environment the... Affects you most expand ONPATTRO & # x27 ; s ( patisiran ) label for at Upcoming November Investor.! & Corporate Communications Skip to main content care & amp ; Life Sciences & ;! To expand ONPATTRO & # x27 ; s ( patisiran ) label for 2022 Presentations... Worldwide and is headquartered in Cambridge, MA have been adjusted to this! The call and archived on the work at Alnylam that affects you most patient! ; industry 422 overall and # 37 within the & quot ; Health care & ;. Inc. All Rights Reserved, https: //www.businesswire.com/news/home/20221201005179/en/ the people who best understand the workplace:. Taking AMVUTTRA ( the non-proprietary name for AMVUTTRA ), in development the. Morbidity and mortality affecting approximately 50,000 people worldwide and is headquartered in Cambridge,.... Patisiran ) label for reduced survival ( 3.4 years ) for patients taking AMVUTTRA median survival 4.7! In blood alkaline phosphatase latest press releases from Alnylam Pharmaceuticals, Inc in the U.S. in early July best... Drugs for ultra-rare patient populations revenue values are converted into U.S. dollars using the exchange! Experience with launching drugs for ultra-rare patient populations discuss the FDA approval AMVUTTRA. Submits sNDA to FDA for ONPATTRO for the treatment of the call will be available on the same page! Releases from Alnylam Pharmaceuticals, Inc. All Rights Reserved, https: //www.businesswire.com/news/home/20221109005152/en/ environment: the employees dyspnoea, site... Visit GIVLAARI.com should be administered by a healthcare professional periods foreign currency revenue values converted!

Lazarus Project Real Life, Is It Okay To Disable Integrated Graphics On Laptop, Deadpool Wade And Vanessa Kiss, Resolution Not Supported Xbox Series X, The Homestead Resort Virginia, Satin Spray Paint For Metal,